Immunotherapy combo shows promise in cervical cancer trial
NCT ID NCT03612791
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tested whether adding the immunotherapy drug atezolizumab to standard chemoradiation helps people with locally advanced cervical cancer. 189 participants received either the combination or standard treatment alone. The goal was to see if the combination delays cancer progression.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Atezolizumab (an immunotherapy drug that helps the immune system fight cancer)
- What this could lead to
- If successful, this could lead to a new standard treatment that delays cancer progression in locally advanced cervical cancer.
- What could go wrong
- This is a phase 2 trial, so results are preliminary. The drug may not improve outcomes and could cause immune-related side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Gustave Roussy
Villejuif, Val de Marne, 94805, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could vitamin d predict cervical cancer treatment success?
- Can a triple-threat approach wipe out cervical cancer before surgery?
- Particle beam and immune therapy join forces against cervical cancer
- Dual immunotherapy plus chemo may shrink cervical tumors before surgery
- Protein clues may predict cervical cancer return
- Could a 3-Week radiation course beat the standard 5-Week for cervical cancer?